Compare Adaptive Biotechnologies Corp (ADPT) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Stitch Fix Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Stitch Fix Inc trades at $3.56 (market cap $495.68M). The key difference: Adaptive Biotechnologies Corp is far larger — about 6.7× Stitch Fix Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | SFIX | |
|---|---|---|
Market Cap | $3.33B | $495.68M |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $5.83 |
52-Week Low | $10.24 | $3.06 |
Enterprise Value | $3.19B | $383.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Stitch Fix (SFIX) trades at $3.72, down 3.12% on the day, as the company continues its turnaround efforts with improving financial metrics. The stock shows bearish technical signals but fundamental progress with narrowing losses, a 43.66% gross margin, and three consecutive quarterly earnings beats. Recent news highlights AI-driven personalization initiatives and growing client spending, though the company remains unprofitable with negative cash flow.
The outlook suggests cautious optimism as SFIX stabilizes revenue near $1.3B and reduces net losses. Investment opportunity lies in the discounted valuation (P/S 0.39) and AI growth potential, but risks include persistent unprofitability, competitive pressure, and execution challenges in achieving sustained positive cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
